tPA Point Mutation at Autolysis Loop Enhances Resistance to PAI-1 Inhibition and Catalytic Activity

Shuangzhou Peng; Guangpu Xue; Shanli Chen; Zhuo Chen; Cai Yuan; Jinyu Li; Mingdong Huang

doi:10.1055/s-0038-1676518

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2019; 119(01): 077-086
DOI: 10.1055/s-0038-1676518

Coagulation and Fibrinolysis

Georg Thieme Verlag KG Stuttgart · New York

tPA Point Mutation at Autolysis Loop Enhances Resistance to PAI-1 Inhibition and Catalytic Activity

Shuangzhou Peng

¹College of Chemistry, Fuzhou University, Fuzhou, Fujian, People's Republic of China

²State Key Laboratory of Structural Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, Fujian, People's Republic of China

³University of Chinese Academy of Sciences, Beijing, People's Republic of China

,

Guangpu Xue

¹College of Chemistry, Fuzhou University, Fuzhou, Fujian, People's Republic of China

,

Shanli Chen

¹College of Chemistry, Fuzhou University, Fuzhou, Fujian, People's Republic of China

,

Zhuo Chen

²State Key Laboratory of Structural Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, Fujian, People's Republic of China

,

Cai Yuan

⁴College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian, People's Republic of China

,

Jinyu Li

¹College of Chemistry, Fuzhou University, Fuzhou, Fujian, People's Republic of China

,

Mingdong Huang

¹College of Chemistry, Fuzhou University, Fuzhou, Fujian, People's Republic of China

²State Key Laboratory of Structural Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, Fujian, People's Republic of China

› Author Affiliations

Abstract

Recombinant tissue-type plasminogen activator (r-tPA) was approved by U.S. Food and Drug Administration as a thrombolytic drug. However, a high dose of r-tPA (up to 100 mg/person) is typically used in clinical applications. Such high dosage leads to severe side effects including haemorrhage and neurotoxicity, which can be fatal. To improve the proteolytic properties of tPA to enhance thrombolytic therapy, we designed a series of mutants in tPA serine protease domain (tPA-SPD) based on the crystal structure of tPA-SPD:plasminogen activators inhibitor-1 (PAI-1) complex that we determined recently. We found that the A146Y substitution in tPA-SPD(A146Y) enhanced resistance to PAI-1 inactivation by 30-fold compared with original tPA-SPD. Interestingly, the tPA-SPD(A146Y) variant showed fivefold higher activation for plasminogen compared with tPA-SPD. The variant also demonstrated thrombolytic activity stronger than tPA-SPD in a clot lysis assay. In vivo, we showed tPA-SPD(A146Y) possessed higher thrombolytic efficacy in a pulmonary embolism model compared with original tPA-SPD. Furthermore, a mouse tail bleeding assay showed that tPA-SPD(A146Y) did not increase bleeding risk compared with clinical drug r-tPA. Together, our findings reveal novel functions of A146Y variant, which not only increases the catalytic efficiency of the enzyme, but also enhances resistance to PAI-1 inhibition, and demonstrating that tPA-SPD (A146Y) variant is a much improved agent for thrombolytic therapy.

Keywords

tissue-type plasminogen activator - PAI-1 resistance - thrombolysis - stroke - bioengineering

Full Text

References

References
1 Marti C, John G, Konstantinides S. , et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J 2015; 36 (10) 605-614
2 Hatcher MA, Starr JA. Role of tissue plasminogen activator in acute ischemic stroke. Ann Pharmacother 2011; 45 (03) 364-371
3 GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329 (10) 673-682
4 Van de Werf FJ, Topol EJ, Sobel BE. The impact of fibrinolytic therapy for ST-segment-elevation acute myocardial infarction. J Thromb Haemost 2009; 7 (01) 14-20
5 Marler JR, Brott T, Broderick J. , et al; National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333 (24) 1581-1587
6 Bruen KJ, Ballard JR, Morris SE, Cochran A, Edelman LS, Saffle JR. Reduction of the incidence of amputation in frostbite injury with thrombolytic therapy. Arch Surg 2007; 142 (06) 546-551
7 Nicole O, Docagne F, Ali C. , et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 7 (01) 59-64
8 Alvarez V, Rossetti AO, Papavasileiou V, Michel P. Acute seizures in acute ischemic stroke: does thrombolysis have a role to play?. J Neurol 2013; 260 (01) 55-61
9 Jang IK, Gold HK, Ziskind AA. , et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79 (04) 920-928
10 Marsh JJ, Konopka RG, Lang IM. , et al. Suppression of thrombolysis in a canine model of pulmonary embolism. Circulation 1994; 90 (06) 3091-3097
11 Farrehi PM, Ozaki CK, Carmeliet P, Fay WP. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 1998; 97 (10) 1002-1008
12 Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999; 99 (23) 3050-3055
13 Konstantinides S, Schäfer K, Thinnes T, Loskutoff DJ. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation 2001; 103 (04) 576-583
14 Brogren H, Karlsson L, Andersson M, Wang L, Erlinge D, Jern S. Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood 2004; 104 (13) 3943-3948
15 Braaten JV, Handt S, Jerome WG, Kirkpatrick J, Lewis JC, Hantgan RR. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. Blood 1993; 81 (05) 1290-1299
16 Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313 (25) 1557-1563
17 Hamsten A, de Faire U, Walldius G. , et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2 (8549): 3-9
18 Gong L, Liu M, Zeng T. , et al. Crystal structure of the Michaelis complex between tissue-type plasminogen activator and plasminogen activators inhibitor-1. J Biol Chem 2015; 290 (43) 25795-25804
19 Jensen JK, Gettins PGW. High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling. Protein Sci 2008; 17 (10) 1844-1849
20 Law RH, Caradoc-Davies T, Cowieson N. , et al. The X-ray crystal structure of full-length human plasminogen. Cell Reports 2012; 1 (03) 185-190
21 Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. GROMACS: fast, flexible, and free. J Comput Chem 2005; 26 (16) 1701-1718
22 Rodriguez R, Chinea G, Lopez N, Pons T, Vriend G. Homology modeling, model and software evaluation: three related resources. Bioinformatics 1998; 14 (06) 523-528
23 Gordon JC, Myers JB, Folta T, Shoja V, Heath LS, Onufriev A. H++: a server for estimating pKas and adding missing hydrogens to macromolecules. Nucleic Acids Res 2005; 33 (Web Server issue): W368-71
24 Berendsen HJC, Vanderspoel D, Vandrunen R. GROMACS - a message-passing parallel molecular-dynamics implementation. Comput Phys Commun 1995; 91 (1–3): 43-56
25 Lindorff-Larsen K, Piana S, Palmo K. , et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins 2010; 78 (08) 1950-1958
26 Jorgensen WL, Chandrasekhar J, Madura JD. , et al. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983; 79 (02) 926-935
27 Hess B, Bekker H, Berendsen HJC. , et al. LINCS: a linear constraint solver for molecular simulations. J Comput Chem 1997; 18 (12) 1463-1472
28 Hoover WG. Canonical dynamics: equilibrium phase-space distributions. Phys Rev A Gen Phys 1985; 31 (03) 1695-1697
29 Parrinello M, Rahman A. Polymorphic transitions in single-crystals - a new molecular-dynamics method. J Appl Phys 1981; 52 (12) 7182-7190
30 Keijer J, Linders M, Wegman JJ, Ehrlich HJ, Mertens K, Pannekoek H. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site. Blood 1991; 78 (05) 1254-1261
31 Gong L, Proulle V, Fang C. , et al. A specific plasminogen activator inhibitor-1 antagonist derived from inactivated urokinase. J Cell Mol Med 2016; 20 (10) 1851-1860
32 Singh S, Houng A, Reed GL. Releasing the brakes on the fibrinolytic system in pulmonary emboli: unique effects of plasminogen activation and α2-antiplasmin inactivation. Circulation 2017; 135 (11) 1011-1020
33 Bdeir K, Murciano JC, Tomaszewski J. , et al. Urokinase mediates fibrinolysis in the pulmonary microvasculature. Blood 2000; 96 (05) 1820-1826
34 Pleines I, Hagedorn I, Gupta S. , et al. Megakaryocyte-specific RhoA deficiency causes macrothrombocytopenia and defective platelet activation in hemostasis and thrombosis. Blood 2012; 119 (04) 1054-1063
35 Björquist P, Brohlin M, Ehnebom J. , et al. Plasminogen activator inhibitor type-1 interacts exclusively with the proteinase domain of tissue plasminogen activator. Biochim Biophys Acta 1994; 1209 (02) 191-202
36 Paoni NF, Keyt BA, Refino CJ. , et al. A slow clearing, fibrin-specific, PAI-1 resistant variant of t-PA (T103N, KHRR 296-299 AAAA). Thromb Haemost 1993; 70 (02) 307-312
37 Keyt BA, Paoni NF, Refino CJ. , et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A 1994; 91 (09) 3670-3674
38 Marcos-Contreras OA, Ganguly K, Yamamoto A. , et al. Clot penetration and retention by plasminogen activators promote fibrinolysis. Biochem Pharmacol 2013; 85 (02) 216-222
39 Gersh KC, Zaitsev S, Cines DB, Muzykantov V, Weisel JW. Flow-dependent channel formation in clots by an erythrocyte-bound fibrinolytic agent. Blood 2011; 117 (18) 4964-4967
40 Absar S, Gupta N, Nahar K, Ahsan F. Engineering of plasminogen activators for targeting to thrombus and heightening thrombolytic efficacy. J Thromb Haemost 2015; 13 (09) 1545-1556
41 Schnee JM, Runge MS, Matsueda GR. , et al. Construction and expression of a recombinant antibody-targeted plasminogen activator. Proc Natl Acad Sci U S A 1987; 84 (19) 6904-6908
42 Dewerchin M, Vandamme AM, Holvoet P. , et al. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase. Thromb Haemost 1992; 68 (02) 170-179
43 Kohmura C, Gold HK, Yasuda T. , et al. A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons. Arterioscler Thromb 1993; 13 (12) 1837-1842
44 Wang X, Palasubramaniam J, Gkanatsas Y. , et al. Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets. Circ Res 2014; 114 (07) 1083-1093
45 Murciano JC, Medinilla S, Eslin D, Atochina E, Cines DB, Muzykantov VR. Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat Biotechnol 2003; 21 (08) 891-896
46 Absar S, Kwon YM, Ahsan F. Bio-responsive delivery of tissue plasminogen activator for localized thrombolysis. J Control Release 2014; 177: 42-50
47 Renatus M, Engh RA, Stubbs MT. , et al. Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA. EMBO J 1997; 16 (16) 4797-4805
48 Ke SH, Tachias K, Lamba D, Bode W, Madison EL. Identification of a hydrophobic exosite on tissue type plasminogen activator that modulates specificity for plasminogen. J Biol Chem 1997; 272 (03) 1811-1816
49 Jiang L, Botkjaer KA, Andersen LM, Yuan C, Andreasen PA, Huang M. Rezymogenation of active urokinase induced by an inhibitory antibody. Biochem J 2013; 449 (01) 161-166
50 Friedrich R, Panizzi P, Fuentes-Prior P. , et al. Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. Nature 2003; 425 (6957): 535-539